PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 71.32

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.19M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 88.29B
HLN Haleon plc

N/A

USD 48.57B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.42B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.46B
CTLT Catalent Inc

N/A

USD 10.91B
ELAN Elanco Animal Health

N/A

USD 6.96B
BHC Bausch Health Companies Inc

N/A

USD 3.04B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.54B
CPHI China Pharma Holdings Inc

N/A

USD 3.66M
YCBD cbdMD Inc

N/A

USD 1.73M

ETFs Containing PBH

NDIA Global X Funds 3.75 % 0.00 %

N/A

USD 0.01B
XST:CA iShares S&P/TSX Capped Co.. 0.00 % 0.61 %

N/A

CAD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.50% 60% D- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.50% 60% D- 72% C
Trailing 12 Months  
Capital Gain 24.71% 53% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.71% 53% F 68% D+
Trailing 5 Years  
Capital Gain 105.59% 93% A 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.59% 93% A 85% B
Average Annual (5 Year Horizon)  
Capital Gain 16.15% N/A N/A 80% B-
Dividend Return 16.15% N/A N/A 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.25% N/A N/A 49% F
Risk Adjusted Return 76.01% N/A N/A 87% B+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector